Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03026166
Title A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

lung small cell carcinoma

Therapies

Ipilimumab + Nivolumab + Rovalpituzumab Tesirine

Nivolumab + Rovalpituzumab Tesirine

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.